These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14563896)

  • 1. Meeting the immense need for HAART in resource-poor settings.
    Bogaards JA; Goudsmit J
    J Antimicrob Chemother; 2003 Nov; 52(5):743-6. PubMed ID: 14563896
    [No Abstract]   [Full Text] [Related]  

  • 2. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.
    Kent DM; McGrath D; Ioannidis JP; Bennish ML
    Clin Infect Dis; 2003 Jul; 37(Suppl 1):S13-24. PubMed ID: 12822128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas?
    Flanigan TP; Wools-Kaloustain K; Harwell J; Cu-Uvin S; Kimaiyo S; Carter EJ
    Clin Infect Dis; 2007 Dec; 45(11):1499-501. PubMed ID: 17990234
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of total lymphocyte count (TLC) as an independent criterion for initiating HAART in resource-poor countries.
    Lee SS; Wong KH
    J Infect; 2005 Jan; 50(1):66-7. PubMed ID: 15603843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Kaposi's sarcoma in resource-limited settings in the era of HAART.
    Lynen L; Zolfo M; Huyst V; Louis F; Barnardt P; Van de Velde A; De Schacht C; Colebunders R
    AIDS Rev; 2005; 7(1):13-21. PubMed ID: 15875657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome.
    Wouters E; Van Damme W; Van Loon F; van Rensburg D; Meulemans H
    Soc Sci Med; 2009 Oct; 69(8):1177-85. PubMed ID: 19692165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment in resource-poor settings: public health research priorities.
    Jaffar S; Govender T; Garrib A; Welz T; Grosskurth H; Smith PG; Whittle H; Bennish ML
    Trop Med Int Health; 2005 Apr; 10(4):295-9. PubMed ID: 15807791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAART--the need for strategically focused investments.
    Feachem R
    Bull World Health Organ; 2001; 79(12):1152-3. PubMed ID: 11842786
    [No Abstract]   [Full Text] [Related]  

  • 10. Prioritising access to antiretroviral therapy in resource-poor settings.
    Lange JM; van der Waals FW
    J HIV Ther; 2002 Aug; 7(3):59-62. PubMed ID: 12442166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inequalities in health: access to treatment for HIV/AIDS.
    Giuliano M; Vella S
    Ann Ist Super Sanita; 2007; 43(4):313-6. PubMed ID: 18209264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.
    Bonnet MM; Pinoges LL; Varaine FF; Oberhauser BB; O'Brien DD; Kebede YY; Hewison CC; Zachariah RR; Ferradini LL
    AIDS; 2006 Jun; 20(9):1275-9. PubMed ID: 16816556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.
    Mekonnen Y; Dukers NH; Sanders E; Dorigo W; Wolday D; Schaap A; Geskus RB; Coutinho RA; Fontanet A
    Ethiop Med J; 2003 Jun; 41 Suppl 1():61-5. PubMed ID: 15227882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges.
    Katabira ET; Oelrichs RB
    AIDS; 2007 Jul; 21 Suppl 4():S5-10. PubMed ID: 17620753
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy in resource-poor settings: scaling up inequalities?
    Egger M; Boulle A; Schechter M; Miotti P
    Int J Epidemiol; 2005 Jun; 34(3):509-12. PubMed ID: 15941732
    [No Abstract]   [Full Text] [Related]  

  • 19. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 20. WHO's HIV/AIDS strategy under the spotlight.
    Kim JY
    Bull World Health Organ; 2004 Jun; 82(6):474-6. PubMed ID: 15356946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.